- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
- RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Key statistics
On Thursday, RemeGen Co Ltd (9995:HKG) closed at 27.65, 84.83% above the 52 week low of 14.96 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.75 |
---|---|
High | 29.45 |
Low | 27.55 |
Bid | 27.65 |
Offer | 27.80 |
Previous close | 29.15 |
Average volume | 1.33m |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 24.52bn HKD |
EPS (TTM) | -3.02 HKD |
Data delayed at least 15 minutes, as of May 23 2024 09:08 BST.
More ▼